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Abstract
The mechanistic target of rapamycin (mTOR) is a critical kinase in the regulation of gene translation and has been
suggested as a potential target for radiosensitization. The goal of this study was to compare the radiosensitizing
activities of the allosteric mTOR inhibitor rapamycin with that of the competitive mTOR inhibitor PP242. On the
basis of immunoblot analyses, whereas rapamycin only partially inhibited mTOR complex 1 (mTORC1) activity and
had no effect on mTOR complex 2 (mTORC2), PP242 inhibited the activity of both mTOR-containing complexes.
Irradiation alone had no effect on mTORC1 or mTORC2 activity. Clonogenic survival was used to define the effects
of the mTOR inhibitors on in vitro radiosensitivity. In the two tumor cell lines evaluated, PP242 treatment 1 hour
before irradiation increased radiosensitivity, whereas rapamycin had no effect. Addition of PP242 after irradiation
also enhanced the radiosensitivity of both tumor lines. To investigate the mechanism of radiosensitization, the
induction and repair of DNA double-strand breaks were evaluated according γH2AX foci. PP242 exposure did
not influence the initial level of γH2AX foci after irradiation but did significantly delay the dispersal of radiation-
induced γH2AX foci. In contrast to the tumor cell lines, the radiosensitivity of a normal human fibroblast cell line
was not influenced by PP242. Finally, PP242 administration to mice bearing U251 xenografts enhanced radiation-
induced tumor growth delay. These results indicate that in a preclinical tumor model PP242 enhances tumor cell
radiosensitivity both in vitro and in vivo and suggest that this effect involves an inhibition of DNA repair.
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Introduction
Emphasis has been placed on the development of molecularly targeted
radiosensitizers, a strategy that requires a thorough understanding of
the mechanisms mediating cellular radioresponse. Along these lines,
radiation-induced posttranslational modifications of existing proteins
(e.g., phosphorylation) have been the subject of extensive investiga-
tion. These modifications have been linked causally to cellular radio-
sensitivity and play important roles in the DNA damage response and
signal transduction pathways. As such, these modifications have pro-
vided a rich source of potential targets for radiosensitization. Recently,
studies have shown radiation to selectively regulate mRNA transla-
tion, a process that operates independently from transcription [1,2].
Of importance to functional consequence, the radiation-induced
changes in mRNA translation correlated to changes in the correspond-
ing protein, in contrast to changes in the radiation-induced transcrip-
tome. Because the translational control of gene expression appears to be
a component of the cellular radioresponse, we recently examined the
role of eukaryotic initiation factor 4E (eIF4E), the rate-limiting com-
ponent in cap-dependent translation initiation, in determining radio-
sensitivity [3]. In that study, eIF4E was shown to participate in the
radiation-induced translation control of gene expression and to be a
tumor-selective target for radiosensitization, which supports the eval-
uation of strategies targeting eIF4E in combination with radiation.
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A primary determinant of eIF4E activity is the mechanistic target of
rapamycin (mTOR), which plays a critical role in regulating mRNA
translation and protein synthesis in response to a variety of environmen-
tal signals [4]. mTOR exists in two distinct complexes: mTOR com-
plex 1 (mTORC1), which includes Raptor, Pras40, Deptor, and Mlst8,
and mTOR complex 2 (mTORC2), which includes Rictor, mSin1,
Protor1/2, and Mlst8 [4]. The major substrates for mTORC1 kinase
activity are eIF4E-binding protein 1 (4E-BP1) and the ribosomal pro-
tein s6 kinase 1 (S6K1). In the hypophosphorylated state, 4E-BP binds
to eIF4E preventing its association with eIF4G, the formation of the
eIF4F complex, and cap-dependent translation [5]. However, when
4E-BP1 is phosphorylated by mTORC1, it is released from eIF4E and
the eIF4F cap complex is assembled [5]. The substrates of mTORC2
are less well defined but include AGC kinases such as AKT, SGK, and
protein kinase C [6]. Of note, mTORC2 phosphorylation of AKT
at s473 can indirectly lead to enhancement mTORC1 activation [7,8].
mTOR is a major downstream effector of a number of signaling
pathways [e.g., phosphatidylinositol 3-kinase (PI3K)/AKT, RAS/
mitogen-activated protein kinase (MAPK), and receptor tyrosine
kinase (RTK)] [4,9]. Because these pathways are frequently activated
or dysregulated in tumors, mTORhas been considered a target for can-
cer therapy [10].Most studies of mTORhave focused on the use of the
allosteric inhibitor rapamycin and its analogs (rapalogs), which incom-
pletely inhibit mTORC1 output and do not inhibit mTORC2 [11].
In the context of cancer treatment, these drugs have shown modest
activity with respect to patient outcomes [12]. The resistance of some
tumors to rapalogs as single agents has been attributed to their incom-
plete inhibition of 4E-BP1 phosphorylation, feedback activation of
AKT, and/or the lack of mTORC2 inhibition [11,13]. In contrast
to the allosteric inhibitors, more recently developed ATP-competitive
inhibitors of mTOR inhibit mTORC1 output more completely and
inhibit mTORC2, which prevents the feedback activation of AKT
following S6K inhibition [7,14–17]. Given mTOR’s role in regulat-
ing eIF4E activity, we have defined the consequences of an allosteric
(rapamycin) and ATP-competitive (PP242) mTOR inhibitor on the
radiosensitivity of tumor and normal cells. The data presented here
indicate that the mTORC1/2 inhibition achieved using the ATP-
competitive inhibitor PP242 enhances tumor cell radiosensitivity in vitro
and in vivo and suggest that this effect involves an inhibition of DNA
double-strand break (DSB) repair.
Materials and Methods
Cell Lines and Treatments
MDA-MB-231 (breast adenocarcinoma) and MRC9 (normal lung
fibroblasts) were obtained from American Type Culture Collection
(ATCC, Manassas, VA) and maintained in Dulbecco’s modified
Eagle’s medium (MDA-MB-231) or minimum essential medium
(MRC9) supplemented with 10% FBS (Invitrogen, Carlsbad, CA).
U251 (glioma) cells were obtained from the Division of Cancer
Treatment and Diagnosis Tumor Repository, National Cancer Insti-
tute (Frederick, MD) and grown in Dulbecco’s modified Eagle’s me-
dium supplemented with 10% FBS. MDA-MB-231 and MRC9 cells
were obtained from ATCC in 2011. ATCC employs short tandem
repeat DNA fingerprinting, karyotyping, and cytochrome C oxidase
to authenticate cell lines. U251 cells were obtained in 2011 from
Division of Cancer Treatment and Diagnosis Tumor Repository.
All cells were cultured less than 6 months after resuscitation. Cell
cultures were maintained in an atmosphere of 5% CO2/95% air at
37°C. PP242 (Sigma-Aldrich, St Louis, MO or Chemdea, Ridgewood,
NJ) and rapamycin (EMD-Biochemicals, Billerica, MA) were dissolved
inDMSO. Cell cultures were irradiated using a 320 kVX-ray source (Pre-
cision X-Ray Inc, North Branford, CT) at a dose rate of 2.3 Gy/min.
Clonogenic Survival Assay
To evaluate radiosensitivity, cells were plated at clonal density in
six-well plates, allowed to attach, followed by the specified drug and/or
radiation treatment protocol. Ten to 14 days after seeding, plates were
stained with 0.5% crystal violet, the number of colonies was deter-
mined, and the surviving fractions were calculated. Radiation survival
curves were generated after normalizing for the cytotoxicity induced by
rapamycin or PP242 treatment alone. Data presented are the means ±
SEM from at least three independent experiments.
Immunoblot Analysis and Antibodies
Cells were lysed in 50mMTris-HCl (pH7.5), 150mMNaCl, 2mM
EDTA, 2 mM EGTA, 25 mM NaF, 25 mM β-glycerophosphate,
0.2% Triton X-100, 0.3% NP-40, and 0.1 mM sodium orthovana-
date, supplemented with 1× phosphatase inhibitor cocktails II and
III (Sigma-Aldrich) and 1× HALT protease inhibitor cocktail (Thermo
Scientific, Waltham, MA) for 15 minutes on ice. Total protein was
quantified with BCA protein assay (Thermo Scientific), separated by
sodium dodecyl sulfate–polyacrylamide gel electrophoresis, transferred
to polyvinylidene difluoride (Bio-Rad, Hercules, CA), and probed with
the indicated antibodies. Bands were visualized with Pierce ECL West-
ern Blotting Substrate (Thermo Scientific). Anti–4E-BP-1, anti-AKT,
anti–phospho-AKT S473, anti–phospho-4E-BP-1 T37/46, and anti–
phospho-4E-BP-1 S65 antibodies were purchased from Cell Signaling
Technology (Beverly, MA). Anti–phospho-S6K T389 and anti-S6K
antibodies were purchased from Epitomics (Burlingame, CA).
Anti–β-actin antibody was obtained from Sigma-Aldrich. Donkey anti-
rabbit and sheep anti-mouse HRP-conjugated secondary antibodies
were purchased from GE Healthcare (Waukesha, WI).
Immunofluorescent Analysis of γH2AX Foci
To visualize foci, cells grown in chamber slides were fixed with
10% neutral buffered formalin, permeabilized with 0.1% Triton
X-100, and blocked with 1% BSA in phosphate-buffered saline
containing 5% goat serum. The slides were incubated with anti-
body to phospho-H2AX (Millipore, Billerica, MA) followed by incu-
bation with goat anti-mouse Alexa 488 (Invitrogen) and mounted
with ProLong Gold Antifade Reagent containing 4′,6-diamidino-2-
phenylindole (DAPI; Invitrogen) to visualize nuclei. Cells were ana-
lyzed on a Leica upright fluorescent microscope.
In Vivo Tumor Growth Delay
Eight to 10-week-old female athymic nude mice (NCr nu/nu;
National Cancer Institute Animal Production Program, Frederick,
MD) were used in these studies. Animals are caged in groups of five
or less and fed animal chow and water ad libitum. A single cell suspen-
sion of U251 (107 cells) was injected subcutaneously into the right
hind leg. When tumors grew to a mean volume of approximately
210 mm3, mice were randomized into four groups: vehicle-treated
controls (5% N -methylpyrrolidone, 15% polyvinylpyrrolidone, and
80% water), PP242 (200 mg/kg), radiation (2 Gy × 4), or PP242/
radiation combination. The treatment was initiated on the day of
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randomization and consisted of PP242 treatment (oral gavage) followed
2 hours later by radiation (2Gy). This treatment was performed for four
consecutive days. Radiation was delivered locally using a Pantak X-Ray
source with animals restrained in a custom designed lead jig. To obtain
tumor growth curves, perpendicular diameter measurements of each
tumor were measured two to three times per week with a digital caliper
and volumes were calculated using the formula (L × W 2)/2. Data are
expressed as means ± SEM tumor volume. Each experimental group
contained five mice. All animal studies were conducted in accordance
with the principles and procedures outlined in the National Institutes
of Health (NIH) Guide for Care and Use of Animals.
Results
To investigate the effects of rapamycin and PP242 on tumor cell radio-
sensitivity, two human cell lines initiated from solid tumors were used:
MDA-MB-231 (breast carcinoma) and U251 (glioma). Initially,
mTORC1 and mTORC2 activities were determined in each cell line
after a 1-hour exposure to PP242 or rapamycin (Figure 1, A and B ).
The goal of this analysis was not only to compare drugs with respect to
inhibitory activity but to also define the minimal concentration of each
drug necessary to elicit the maximally achievable mTOR kinase inhibi-
tion. Toward this end, the levels of p-S6K (t389) and p-4E-BP1 (t37/
46 and s65) were used as readouts for mTORC1 activity; p-AKT
(s473) was used as a marker for mTORC2 activity. Rapamycin expo-
sure reduced p-S6K and marginally reduced p-4E-BP1 levels in both
cell lines with essentially the same reductions induced by 5 and 10 nM.
No further reductions in these indicators of mTORC1 activity were
achieved by increasing rapamycin concentrations out to 500 nM (data
not shown), consistent with previous reports [12,18]. PP242 exposure
(1 and 2 μM) reduced p-S6K levels to a similar degree as rapamycin.
However, PP242 was considerably more effective at reducing the levels
of p-4E-BP1 than rapamycin, as previously shown [14,15]. In contrast to
rapamycin, PP242 inhibited the phosphorylation of AKT at s473 in both
tumor cell lines, indicative of an inhibition of mTORC2 activity. Thus,
as reported for other cell lines [14,15], in U251 andMDA-MB-231 cells,
PP242 inhibits the rapamycin-resistant functions of mTOR.
To determine whether irradiation influences mTOR activity,
U251 and MDA-MB-231 cells were exposed to 2 Gy and collected
for immunoblot analysis at times out to 6 hours (Figure 2, A and B).
On the basis of levels of p-AKT, p-S6K, and p-4E-BP1, radiation did
not increase mTORC1 or mTORC2 activity in either of these tumor
cell lines. These measures were conducted using cells grown under
optimal in vitro conditions (i.e., 10% FBS) applicable to clonogenic
survival analysis. Whereas previous reports showed that radiation in-
creased mTORC1 and mTORC2 activities in tumor cells, those
studies were performed using serum-starved cells [19,20].
The effects of the mTOR inhibitors on tumor cell radiosensitivity
as measured by clonogenic survival analysis are shown in Figure 3, A
and B. For this study, cells were plated at clonogenic density and
allowed to attach (5–6 hours); the indicated concentration of inhib-
itor was added 1 hour before irradiation. Twenty-four hours after
irradiation, medium was removed, fresh drug-free medium was
added, and colonies were determined 10 to 14 days later. On the
basis of the data shown in Figure 1, a concentration of 10 nM rapa-
mycin was used, which induces the maximum achievable level of
mTORC1 inhibition. Rapamycin (10 nM, 25 hours) alone did
not reduce the surviving fraction of U251 cells. Moreover, addition
of rapamycin 1 hour before irradiation had no effect on the radio-
sensitivity of U251 cells (Figure 3A). In U251 cells, 1 and 2 μM
PP242 added 1 hour before irradiation increased radiosensitivity in
a dose-dependent manner (Figure 3A), consistent with its dose-
dependent mTOR inhibition (Figure 1A), resulting in dose enhance-
ment factors (DEFs) at a surviving fraction of 0.1 of 1.27 and 1.52,
respectively. PP242 alone at 2 μM slightly reduced the U251 surviv-
ing fraction to 0.91 ± 0.04 and had no effect on survival at 1 μM. To
determine whether these effects were unique to U251 cells, a similar
analysis was used for MDA-MB-231 cells (Figure 3B). Rapamycin
(10 nM, 25 hours) alone had no effect on the surviving fraction of
MDA-MB-231 cells and had no effect on the radiosensitivity of
MDA-MB-231 cells. PP242 (2 μM, 25 hours) alone reduced surviv-
ing fraction of MDA-MB-231 cells to 0.83 ± 0.06; PP242 added
1 hour before irradiation enhanced their radiosensitivity with a
Figure 1. Effects of rapamycin and PP242 on mTORC1/2 activity. (A) U251 and (B) MDA-MB-231 cells were treated for 1 hour with the
specified dose of inhibitor. Cells were collected and subjected to immunoblot analysis. Actin was used as a loading control.
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Figure 2. The effect of radiation on mTOR activity. (A) U251 and (B) MDA-MB-231 cells were irradiated (2 Gy) and collected at the spec-
ified times and subjected to immunoblot analysis. Actin was used as a loading control. Immunoblots are representative of two inde-
pendent experiments.
Figure 3. Effects of mTOR inhibitors on cellular radiosensitivity. (A) U251, (B) MDA-MB-231, and (C) MRC9 cells were plated and allowed
to attach for 5 to 6 hours, and the indicated concentration of inhibitor was added 1 hour before irradiation. Twenty-four hours after
irradiation, medium was removed and fresh drug-free medium was added. Colony-forming efficiency was determined 10 to 14 days
later and survival curves were generated after normalizing for cell killing from drug alone. Values shown represent the means ± SEM for
three independent experiments.
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DEF of 1.34. These data suggest that in contrast to the allosteric
mTOR inhibitor rapamycin, the ATP-competitive inhibitor
PP242, which more completely inhibits mTORC1 and inhibits
mTORC2, enhances radiation-induced cell killing. The same experi-
ment using PP242 was performed using the normal lung fibroblast line,
MRC9 (Figure 3C). PP242 alone had no effect onMRC9 survival and,
in contrast to the tumor cell lines, had no effect on the radiosensitivity
of MRC9 cells. These results suggest that PP242 induces a tumor-
selective increase in radiosensitivity.
The critical lesion responsible for radiation-induced cell death is the
DNA DSB. Because γH2AX foci correspond to radiation-induced
DSBs and their dispersal correlates with DSB repair [21,22], the effects
of PP242 on radiation-induced γH2AX were evaluated in U251 and
MDA-MB-231 cells (Figure 4, A and B ). In this study, PP242 was
added 1 hour before irradiation (2 Gy) with γH2AX nuclear foci deter-
mined at times out to 24 hours. In U251 cells 1 hour after irradiation,
no difference in foci levels was detected between control (vehicle) and
PP242-treated cells, suggesting that mTOR inhibition had no effect on
the initial levels of radiation-induced DSBs. However, at 6 and 24 hours
after irradiation (2 Gy), the number of γH2AX foci remaining in the
PP242 (1 and 2 μM)–treated cells was significantly greater than in con-
trol cells. This effect was PP242 dose-dependent, consistent with the
dose-dependent effect on radiosensitivity in U251 cells. In MDA-
MB-231 cells 1 hour after irradiation, no difference in foci levels
was detected between vehicle-treated and PP242-treated cells. How-
ever, at 24 hours after irradiation, the number of γH2AX foci remain-
ing in the PP242 (2 μM)–treated cells was significantly greater than in
vehicle-treated cells. These data suggest that PP242 induces radiosen-
sitization through an inhibition of the repair of radiation-induced
DNA DSBs.
In the initial treatment protocol evaluating the effects of PP242 on
radiosensitivity (Figure 2), the mTOR inhibitor was added to the
culture media 1 hour before irradiation. To determine whether this
was the optimal exposure protocol for radiosensitization as well as to
generate insight into the mechanisms involved, PP242 (2 μM) was
added to culture media at various times before or after irradiation
followed by clonogenic survival analysis. In each experiment, PP242
was removed 24 hours after exposure to radiation and all survival curves
were generated after normalizing for cell killing caused by PP242 treat-
ment alone. Addition of PP242 immediately after irradiation enhanced
the radiosensitivity of U251 cells (Figure 5A) with a DEF of 1.60.
Addition of PP242 at 1 and 6 hours after irradiation also resulted in
radiosensitization (DEFs of 1.50 and 1.26, respectively), although
the enhancement was substantially less for the 6-hour time point
(Figure 5B). Treatment of U251 cells with PP242 24 hours before
irradiation did not enhance their radiosensitivity (Figure 5B). These
treatment protocols were also evaluated using MDA-MB-231 cells
(Figure 5C ). PP242 exposure for 24 hours before irradiation had no
effect on the radiosensitivity of MDA-MB-231 cells, whereas drug
addition immediately or 1 hour after irradiation enhanced radiosen-
sitivity (DEFs of 1.88 and 1.71, respectively) with the sensitization
also present, albeit diminished, at the 6-hour time point (DEF of 1.31).
The data presented in Figure 5 indicate that the PP242-induced radio-
sensitization also occurs when the drug was added to culture media
after irradiation.
To determine whether the enhancement of tumor cell radiosensi-
tivity measured in vitro extends to an in vivo tumor model, U251
cells were grown as xenografts in nude mice. Initially, the ability of
PP242 to inhibit mTOR activity in U251 xenografts was defined.
PP242 (100 or 200 mg/kg) was delivered by oral gavage to mice
bearing U251 leg tumors; 6 hours later, tumors were collected and
subjected to immunoblot analysis. As shown in Figure 6A, a consistent
reduction of p-AKT and p-4E-BP1 levels, indicative of mTORC2 and
mTORC1 inhibition, respectively, was detected in tumors isolated
from mice that received the PP242 at 200 mg/kg. On the basis of these
results, a combination protocol was designed using 200 mg/kg PP242
and 2 Gy, and the consequences on U251 tumor growth rate were
determined. Specifically, mice bearing U251 leg tumors (∼210 mm3)
were randomized into four groups: vehicle, PP242, radiation, and
PP242 plus radiation. PP242 was delivered once a day (200mg/kg, oral
gavage) for 4 days with the tumor locally irradiated (2 Gy) 2 hours after
each of the four drug treatments. The growth rates of U251 tumors
exposed to each treatment are shown in Figure 6B. For each group,
the time to grow from 210mm3 (volume at time of treatment initiation)
Figure 4. Influence of PP242 on radiation-induced γH2AX foci. (A) U251 and (B) MDA-MB-231 cells were exposed to the indicated dose
of PP242 1 hour before irradiation (2 Gy). Cells were collected at the specified time; γH2AX foci were counted in at least 50 nuclei per
condition. Values shown represent the means ± SEM for three independent experiments; *P < .05 according to Student’s t test (PP242
compared to control).
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Figure 5. The effects of the timing of PP242 treatment on cellular radiosensitivity. (A, B) U251 and (C) MDA-MB-231 cells were plated
and allowed to attach. Cells were then exposed to PP242 (2 μM) either 24 hours before irradiation (24 hours pre-IR), immediately after
(immediately post-IR), 1 hour after (1 hour post-IR), or 6 hours after (6 hours post-IR) irradiation. Medium was removed and fresh drug-
free medium was added 24 hours after irradiation. Colony-forming efficiency was determined 10 to 14 days later and survival curves were
generated after normalizing for cell killing from drug alone. Values shown represent the means ± SEM for three independent experiments.
Figure 6. The effects of PP242 on radiation-induced tumor growth delay. (A) Mice bearing U251 glioma xenografts were exposed to
vehicle or PP242 (oral gavage) at the indicated dose. Six hours later, tumors were collected and subjected to immunoblot analysis using
actin as a loading control. Each lane represents the tumor from an individualmouse. (B)WhenU251 tumors reached approximately 210mm3
in size,micewere randomized into four groups: vehicle, PP242 (200mg/kgadministeredoncedaily byoral gavage), radiation (2Gyoncedaily),
andPP242plus radiation. PP242wasdelivered once a day (200mg/kg byoral gavage) for 4 dayswith the tumor locally irradiated (2Gy) 2 hours
after each of the four drug treatments. Each group contained five mice. Values represent the mean tumor volumes ± SEM.
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to 1000mm3 was calculated using the tumor volumes from the individ-
ual mice in each group (mean ± SEM). These data were then used to
determine the absolute growth delays (the time in days for tumors in
treated mice to grow from 210 to 1000 mm3 minus the time in days
for tumors to reach the same size in vehicle-treated mice).
For U251 tumors (Figure 6B), the absolute growth delays for the
PP242 alone and radiation alone groups were 1.0 ± 0.4 and 12.9 ±
2.1 days, respectively. The growth delay in mice treated with the
combination of PP242 and radiation was 20.0 ± 1.3 days, which is
greater than the sum of the growth delays caused by PP242 alone and
radiation alone. To obtain a DEF comparing the tumor radio-
response in mice with and without PP242 treatment, the normalized
tumor growth delays were determined, which accounts for the con-
tribution of PP242 to tumor growth delay induced by the combina-
tion treatment. Normalized tumor growth delay was defined as the
time in days for tumors to grow from 210 to 1000 mm3 in mice
exposed to the combined modality minus the time in days for tumors
to grow from 210 to 1000 mm3 in mice treated with PP242 only.
The DEF, obtained by dividing the normalized tumor growth delay
in mice treated with the radiation/PP242 combination (19.0) by the
absolute growth delay in mice treated with radiation only (12.9), was
1.5. Thus, whereas PP242 delivered alone had no significant effect
on U251 tumor growth, the ATP-competitive mTOR inhibitor
enhanced the radiation-induced tumor growth delay.
Discussion
Previous investigations into mTOR as a potential target for tumor
cell radiosensitization have focused on rapamycin and various rapa-
logs. The conclusions of such studies have been somewhat inconsis-
tent with radiosensitization detected for some tumor cell lines
[19,20,23] but not others [24–26]. Clearly, such inconsistencies
may be attributed to cell-type specificity and/or differences in treat-
ment protocols. However, an additional complicating factor is that
rapamycin is an incomplete inhibitor of mTOR kinase. That is,
although rapamycin inhibits the S6K phosphorylation mediated by
mTORC1, it only partially inhibits mTORC1-dependent 4E-BP1
phosphorylation and does not inhibit mTORC2 activity [11].
Consequently, attempts to correlate radiosensitization with targeting
of mTOR have been limited to the evaluation of S6K phosphoryla-
tion [19,20,23–25]. Along these lines, in a study that evaluated mul-
tiple rapamycin concentrations, Murphy et al. showed that exposure
of sarcoma cell lines to 300 nM rapamycin resulted in radiosensitiza-
tion, yet 3 nM was sufficient to eliminate detectable levels of p-S6K,
a concentration that had no effect on radiosensitivity [20]. Thus, as
illustrated by this study, the relationship between rapamycin, mTOR
activity, and radiosensitization is unclear. To better understand the
potential for mTOR to serve as a target for radiosensitization, we
defined the radiosensitivity of tumor cells treated with the ATP-
competitive mTOR inhibitor PP242, which in addition to inhibiting
S6K activation, inhibits 4E-BP phosphorylation as well as mTORC2
activity [14,15]. The data presented here show that for the two human
tumor cell lines evaluated PP242 exposure, in contrast to rapamycin,
enhanced radiation-induced cell killing.
Given the number of mTORC1 and mTORC2 substrates, whether
PP242-induced radiosensitization is initiated through a single down-
stream event or whether multiple mTOR substrates are involved
remains to be determined. However, as previously reported [14,27,28]
and shown here, although rapamycin and PP242 inhibit S6K phos-
phorylation to approximately the same degree, PP242 exposure results
in a considerably more effective inhibition of 4E-BP1 phosphoryla-
tion. Feldman et al. [14] reported that the PP242-mediated inhibi-
tion of 4E-BP1 phosphorylation prevents its release of eIF4E, thus
reducing the level of eIF4E available for cap-dependent translation.
Such a scenario would be consistent with our recent data showing
that reduced eIF4E levels increase tumor cell radiosensitivity [3] and
suggests that inhibiting the mTOR-mediated phosphorylation of
4E-BP1 at least plays a role in PP242-induced radiosensitization.
On the basis of the analysis of γH2AX foci induction and disper-
sion, it appears that PP242-mediated radiosensitization is the result
of an inhibition of DNA DSB repair. Furthermore, the radiosensiti-
zation obtained when PP242 was added at times out to 6 hours after
irradiation suggests that mTOR inhibition affects a later stage in the
DNA repair process. Although the direct interaction of mTOR or
one of its substrates with a component of the DNA repair machinery
cannot be eliminated, the role of mTOR as a critical regulator of
gene translation in response to a variety of stress and environmental
signals may also provide a mechanistic basis for the inhibition of
DSB repair in PP242-treated cells. A recent study using microarray
analysis of polysome-bound RNA showed that after PP242 exposure,
among the genes whose translation was significantly suppressed in-
cluded a number corresponding toDNA repair proteins [28]. Ribosome
profiling also indicated that among the genes whose translation was
reduced after PP242 exposure were a number involved in DNA repair
[29].With respect to the effects of PP242 on radiosensitivity,microarray
analysis of polysome-bound RNA has shown that radiation-induced
changes in gene expression can be primarily attributed to translational
control processes [1,2]. Moreover, in our recent study using RIP-Chip
analysis [3], irradiation of MDA-MB-231 cells was found to increase
eIF4E binding to more than 1000 unique transcripts, a significant
number of which were associated with the functional category of DNA
replication, recombination, and repair. Thus, the PP242-mediated
inhibition of gene translation may also play a role in its radiosensitizing
actions, which will be the subject of future studies.
It has previously been reported that mTOR activity is increased at
15 minutes after irradiation with a return to control levels by 1 hour
[30]. Whereas we did not evaluate mTOR activity at times less than
1 hour after irradiation, addition of PP242 at times up to 6 hours
after irradiation was shown to result in radiosensitization. This would
suggest that if there was a transient increase in mTOR activity after
irradiation returning to control levels by 1 hour, it was not critical to
the mechanism of PP242-induced radiosensitization. Furthermore,
the study by Contessa et al. used serum-starved cells, which results
in a reduction in basal mTOR activity compared to standard growth
conditions [30]. In contrast, in the current study, the effects of radia-
tion on mTOR activity were determined under the same conditions as
clonogenic survival analysis (media supplemented with 10% serum).
Whereas PP242 exposure enhanced the radiosensitivity of human
tumor cell lines, the same procedure had no effect on the radiosen-
sitivity of the normal fibroblast line MRC9. Because mTOR activity
in MRC9 cells was reduced by PP242 treatment to the same extent
as in the tumor cells (data not shown), the lack of radiosensitization
may reflect the previously established fundamental differences in
mTOR activity and/or function in tumor versus normal cells [8].
To further evaluate the clinical potential of PP242 delivered in combi-
nation with radiotherapy, its effects on mTOR activity and radiation-
induced tumor growth delay were defined in a preclinical model system.
Although PP242 inhibited mTOR activity in U251 xenografts, drug
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delivery for 4 days had no significant effect on tumor growth rate,
which is in contrast to previous studies showing substantial tumor
growth inhibition with prolonged daily PP242 treatment [15,31].
However, this drug treatment protocol did result in a significant
increase in radiation-induced tumor growth delay. A number of ATP-
competitive mTOR inhibitors are being evaluated in clinical trials [32].
The data presented here showing that PP242 enhances tumor cell
radiosensitivity both in vitro and in vivo suggest that these inhibitors
delivered in combination with radiotherapy may be of value as a cancer
treatment strategy.
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